The use of antihypertensive drugs, which include angiotensin-converting enzyme inhibitors (ACEi), calcium channel blockers (CCBs), beta-adrenoceptor blockers (BBs), angiotensin receptor blockers (ARBs) and thiazide diuretics, is a critical component in MASLD management, since hypertension showed an independent association with HCC risk and poor prognosis (117). Here, ACE is linked to hepatocellular carcinoma.